A recent publication suggested that only non-selective β-blockers were effective at decreasing mortality in ovarian cancer patients [15], thus we stratified our Stage I breast cancer patients based on β-AR selectivity. This evidence concerns the gene ADRB2 and ovarian carcinoma.